The case of food botulism F

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

This case describes a rare case of food botulism F in a 42-year-old man, which developed after he ate dried fish. The disease proceeded in a severe form with the development of ophthalmoplegia, tetraparesis, and respiratory failure. Monovalent antitoxic serums against botulinum toxins A, B, and E were administered to the patient. However, on the third day of the disease, he developed fulminant toxic myocarditis with asystole. Despite successful resuscitation, the patient developed a post-resuscitation disease and anoxic encephalopathy. The disease was complicated by severe aspiration pneumonia caused by Klebsiella pneumoniae (ESBL+). The duration of mechanical ventilation was 12 days. His hemodynamics stabilized on the eighth day of illness, and on the 19th day of illness, physical activity and a state of minimal consciousness appeared. The patient was transferred to the rehabilitation department on the 22nd day of the illness.

Doctors should be informed about the possibility of the development and severity of botulism caused by botulinum toxin type F. It is necessary to introduce polyvalent antibotulinic serum into clinical practice, including antitoxins against rare types of botulinum toxin.

About the authors

Irina V. Nikolaeva

Kazan State Medical University

Author for correspondence.
Email: irinanicolaeva@mail.ru
ORCID iD: 0000-0003-0104-5895
SPIN-code: 4103-5663

MD, Dr Sci. (Med.), Professor

Russian Federation, Kazan

Fayruza S. Gilmullina

Kazan State Medical University

Email: fayruza.gilmullina@yandex.ru
ORCID iD: 0000-0002-3015-8920
SPIN-code: 8620-0710

MD, Cand. Sci. (Med.), Associate Professor

Russian Federation, Kazan

Aleksander Yu. Kazancev

Republican Clinical Hospital of Infectious Diseases named after A.F. Agafonov

Email: engine90@bk.ru
ORCID iD: 0000-0001-9800-9940
SPIN-code: 4888-8556

MD, Cand. Sci. (Med.)

Russian Federation, Kazan

Bulat Sh. Fatkullin

Republican Clinical Hospital of Infectious Diseases named after A.F. Agafonov

Email: bulat.fatkullin.68@bk.ru
SPIN-code: 8772-3423

MD, Cand. Sci. (Med.)

Russian Federation, Kazan

References

  1. Nikiforov VV, Tomilin YuN, Davydov AV, et al. The case of severe botulism: artificial ventilation of lungs for 127 days. Epidemiology and Infectious Diseases. 2013;18(6):49–57. (In Russ). doi: 10.17816/EID40793
  2. Rao AK, Sobel J, Chatham-Stephens K, Luquez C. Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021. MMWR Recomm Rep. 2021;70(2):1–30. doi: 10.15585/mmwr.rr7002a1
  3. Smith TJ, Hill KK, Raphael BH. Historical and current perspectives on Clostridium botulinum diversity. Res Microbiol. 2015;166(4):290–302. doi: 10.1016/j.resmic.2014.09.007
  4. Mazuet C, Legeay C, Sautereau J, et al. Characterization of Clostridium Baratii Type F Strains Responsible for an Outbreak of Botulism Linked to Beef Meat Consumption in France. PLoS Curr. 2017;9.
  5. Hall JD, McCroskey LM, Pincomb BJ, Hatheway CL. Isolation of an organism resembling Clostridium barati which produces type F botulinal toxin from an infant with botulism. J Clin Microbiol. 1985;21(4):654–655. doi: 10.1128/jcm.21.4.654-655.1985
  6. Sobel J, Dill T, Kirkpatrick CL, et al. Clinical recovery and circulating botulinum toxin type F in adult patient. Emerg Infect Dis. 2009;15(6):969–971. doi: 10.3201/eid1506.070571
  7. Gupta A, Sumner CJ, Castor M, Maslanka S, Sobel J. Adult botulism type F in the United States, 1981–2002. Neurology. 2005;65(11):1694–1700. doi: 10.1212/01.wnl.0000187127.92446.4c
  8. Moodley A, Quinlisk P, Garvey A, et al.; Centers for Disease Control and Prevention (CDC). Notes from the field: infant botulism caused by Clostridium baratii type F — Iowa, 2013. MMWR Morb Mortal Wkly Rep. 2015;64(14):400.
  9. Tréhard H, Poujol I, Mazuet C, et al. A cluster of three cases of botulism due to Clostridium baratii type F, France, August 2015. Euro Surveill. 2016;21(4). doi: 10.2807/1560-7917.ES.2016.21.4.30117
  10. Yu PA, Lin NH, Mahon BE, et al. Safety and Improved Clinical Outcomes in Patients Treated With New Equine-Derived Heptavalent Botulinum Antitoxin. Clin Infect Dis. 2017;66(Suppl. 1):S57–S64. doi: 10.1093/cid/cix816

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2022 Nikolaeva I.V., Gilmullina F.S., Kazancev A.Y., Fatkullin B.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies